{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:16:58Z","timestamp":1762377418156,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00415-023-11865-1","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T18:02:22Z","timestamp":1689616942000},"page":"5196-5200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim"],"prefix":"10.1007","volume":"270","author":[{"given":"Paula","family":"Lombardo-del Toro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Bragado-Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-4850","authenticated-orcid":false,"given":"Pablo","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Tena-Cucala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Matas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-865X","authenticated-orcid":false,"given":"Albert","family":"Mu\u00f1oz-Vendrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-8291","authenticated-orcid":false,"given":"Albert","family":"Pons-Escoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-0180","authenticated-orcid":false,"given":"Antonio","family":"Mart\u00ednez-Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-2040","authenticated-orcid":false,"given":"Sergio","family":"Mart\u00ednez-Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8054-0565","authenticated-orcid":false,"given":"Luc\u00eda","family":"Romero-Pinel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"11865_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese I, Reich DS, Nath A (2021) Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 17:37\u201351. https:\/\/doi.org\/10.1038\/s41582-020-00427-y","journal-title":"Nat Rev Neurol"},{"key":"11865_CR2","doi-asserted-by":"publisher","first-page":"577721","DOI":"10.1016\/j.jneuroim.2021.577721","volume":"360","author":"S Sriwastava","year":"2021","unstructured":"Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, Saber H, Tripathi R, Sheikh Z, Peterson S, Gwinn R, Bernitsas E (2021) Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol 360:577721. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577721","journal-title":"J Neuroimmunol"},{"key":"11865_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00415-021-10952-5","volume":"269","author":"N M\u00f6hn","year":"2022","unstructured":"M\u00f6hn N, Grote-Levi L, Hopfner F, Eiz-Vesper B, Maecker-Kolhoff B, Warnke C, S\u00fchs K-W, Wattjes MP, H\u00f6glinger GU, Skripuletz T (2022) Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. J Neurol 269:2403\u20132413. https:\/\/doi.org\/10.1007\/s00415-021-10952-5","journal-title":"J Neurol"},{"key":"11865_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/acn3.776","volume":"6","author":"D Stefoski","year":"2019","unstructured":"Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Morales FS (2019) Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol 6:923\u2013931. https:\/\/doi.org\/10.1002\/acn3.776","journal-title":"Ann Clin Transl Neurol"},{"key":"11865_CR5","doi-asserted-by":"publisher","first-page":"E1815","DOI":"10.1212\/wnl.0000000000005529","volume":"90","author":"JR Berger","year":"2018","unstructured":"Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M (2018) Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90:E1815\u2013E1821. https:\/\/doi.org\/10.1212\/wnl.0000000000005529","journal-title":"Neurology"},{"key":"11865_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","volume":"21","author":"T Dong-Si","year":"2015","unstructured":"Dong-Si T, Gheuens S, Gangadharan A et al (2015) Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J NeuroVirology 21:637\u2013644. https:\/\/doi.org\/10.1007\/s13365-015-0316-4","journal-title":"J NeuroVirology"},{"key":"11865_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12883-019-1407-2","volume":"19","author":"T Sinnecker","year":"2019","unstructured":"Sinnecker T, Hadisurya J, Schneider-Hohendorf T et al (2019) Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC Neurol 19:190. https:\/\/doi.org\/10.1186\/s12883-019-1407-2","journal-title":"BMC Neurol"},{"key":"11865_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12883-022-02839-3","volume":"22","author":"D Mickeviciene","year":"2022","unstructured":"Mickeviciene D, Baltusiene A, Afanasjeva B, Afanasjevas D, Gleizniene R, Rastenyte D, Berger JR (2022) Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report. BMC Neurol 22:306. https:\/\/doi.org\/10.1186\/s12883-022-02839-3","journal-title":"BMC Neurol"},{"key":"11865_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40261-016-0433-8","volume":"36","author":"Y Jamilloux","year":"2016","unstructured":"Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, S\u00e8ve P (2016) Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clin Drug Investig 36:783\u2013789. https:\/\/doi.org\/10.1007\/s40261-016-0433-8","journal-title":"Clin Drug Investig"},{"key":"11865_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","volume":"19","author":"DB Clifford","year":"2013","unstructured":"Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L, Zhao Z, Duda P (2013) A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J NeuroVirology 19:351\u2013358. https:\/\/doi.org\/10.1007\/s13365-013-0173-y","journal-title":"J NeuroVirology"},{"key":"11865_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ana.26198","volume":"90","author":"R Bernard-Valnet","year":"2021","unstructured":"Bernard-Valnet R, Koralnik IJ, Du Pasquier R (2021) Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol 90:865\u2013873. https:\/\/doi.org\/10.1002\/ana.26198","journal-title":"Ann Neurol"},{"key":"11865_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/13524585221137279","volume":"29","author":"AW Barritt","year":"2022","unstructured":"Barritt AW, Das E, Morley N, Seymour M, Saha R, Vera J, Vundavalli S, Dizdarevic S, Nicholas R, Berger JR, Fisniku LK (2022) Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis. Mult Scler 29:301\u2013306. https:\/\/doi.org\/10.1177\/13524585221137279","journal-title":"Mult Scler"},{"key":"11865_CR13","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s00415-021-10414-y","volume":"268","author":"D Roos-Weil","year":"2021","unstructured":"Roos-Weil D, Weiss N, Guihot A et al (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? J Neurol 268:2458\u20132465. https:\/\/doi.org\/10.1007\/s00415-021-10414-y","journal-title":"J Neurol"},{"key":"11865_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","volume":"195","author":"HM Mehta","year":"2015","unstructured":"Mehta HM, Malandra M, Corey SJ (2015) G-CSF and GM-CSF in neutropenia. J Immunol 195:1341\u20131349. https:\/\/doi.org\/10.4049\/jimmunol.1500861","journal-title":"J Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11865-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11865-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11865-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:03:56Z","timestamp":1697274236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11865-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["11865"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11865-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"17 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paula Lombardo-del Toro received funding for travel and congress attendance from Novartis and Lilly. Irene Bragado-Trigo, Pablo Arroyo, Raquel Tena-Cucala, Laura Bau, Elisabet Matas, Albert Mu\u00f1oz-Vendrell, Antonio Mart\u00ednez-Y\u00e9lamos, Sergio Mart\u00ednez-Y\u00e9lamos and Luc\u00eda Romero-Pinel received honorarium for participating on advisory boards and for collaborations as consultants and for their work on scientific communications; they also received research support as well as funding for travel and congress-attending expenses from Roche, Biogen Idec, Novartis, TEVA, Merck, Genzyme, Sanofi, Bayer, Almirall, Horizon and Celgene. Marta Sim\u00f3 and Albert Pons-Escoda declare nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethics Committee approval was not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient and her relatives before publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}}]}}